Trial Profile
An open label study to assess the efficacy, safety and tolerability of pyronaridine-artesunate (Pyramax) in the treatment of malaria infection caused by single or mixed species of Plasmodium falciparum, P. vivax, or P. malariae in Vietnamese patients living in Dak Nong Province, central west-highlands of Vietnam
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Artesunate/pyronaridine (Primary)
- Indications Falciparum malaria; Malaria; Vivax malaria
- Focus Therapeutic Use
- 27 Sep 2021 Status changed from recruiting to completed.
- 27 Sep 2021 Results published in the Antimicrobial Agents and Chemotherapy
- 03 Sep 2018 New trial record